文章摘要
钱 荣,郭小红,徐艳艳,俞小卫,钱 骅.唑来膦酸和伊班膦酸钠治疗恶性肿瘤骨转移的成本-效用分析[J].,2022,(23):4581-4585
唑来膦酸和伊班膦酸钠治疗恶性肿瘤骨转移的成本-效用分析
Cost-utility Analysis of Zoledronic Acid and Sodium Ibandronate in the Treatment of Bone Metastasis from Malignant Tumors
投稿时间:2022-04-27  修订日期:2022-05-23
DOI:10.13241/j.cnki.pmb.2022.23.036
中文关键词: 恶性肿瘤  骨转移  唑来膦酸  伊班膦酸钠  疗效  成本-效用分析
英文关键词: Malignant tumor  Bone metastasis  Zoledronic acid  Sodium ibandronate  Curative effect  Cost-utility analysis
基金项目:2021年江苏省药学会-恒瑞医院药学基金项目(H202143);2020年南通市科技局科技计划指导性项目(MSZ20215);2020年南通市药学会-常州四药医院药学科研基金项目(ntyx2022)
作者单位E-mail
钱 荣 南通大学附属肿瘤医院药剂科 江苏 南通 226361 qianrong1016@163.com 
郭小红 南通大学附属肿瘤医院药剂科 江苏 南通 226361  
徐艳艳 南通大学附属肿瘤医院药剂科 江苏 南通 226361  
俞小卫 南通大学附属肿瘤医院药剂科 江苏 南通 226361  
钱 骅 南通大学附属肿瘤医院药剂科 江苏 南通 226361  
摘要点击次数: 9
全文下载次数: 11
中文摘要:
      摘要 目的:评价唑来膦酸和伊班膦酸钠治疗恶性肿瘤骨转移患者的经济性。方法:回顾性分析2020年1月-2022年1月于×医院就诊的86例恶性肿瘤骨转移病例,其中46例使用唑来膦酸治疗(A组),40例使用伊班膦酸钠治疗(B组),对比两组疼痛控制效果、不良反应发生情况及简明健康状况测量量表(SF-36)评分,同时汇总两种治疗方案的成本,运用药物经济学原理进行成本-效用分析。结果:A组疼痛控制率为82.61%,与B组的85.00%比较无统计学差异(P>0.05);治疗后,两组SF-36评分中的生理功能(PF)、生理职能(RP)、躯体疼痛(BP)、总体健康(GH)、社会功能(SF)、精神健康(MH)、情感职能(RE)、活力(VT)均较治疗前明显升高(P<0.05),但组间比较差异均无统计学意义(P>0.05);A组、B组不良反应发生率相似,差异无统计学意义(P>0.05);A组药品成本(C1)和总成本(C)分别为(4052.50±80.50)元、(4453.87±123.56)元,高于B组的(2025.50±70.15)元和(2395.44±109.17)元,差异均有统计学意义(P<0.05);A组成本-效用比(CUR)采用SF-36量表评分评判为4189.94,B组为2829.17。结论:考虑药物的有效性及经济性,采用伊班膦酸钠治疗恶性肿瘤骨转移具有明显的成本-效用优势,值得临床推广应。
英文摘要:
      ABSTRACT Objective: To evaluate the economy of zoledronic acid and sodium ibandronate in the treatment of bone metastasis from malignant tumors. Methods: This study retrospectively reviewed 86 patients with bone metastasis from malignant tumors who were admitted to the hospital from January 2020 to January 2022. 46 patients treated with zoledronic acid were included in group A, and 40 patients treated with sodium ibandronate were included in group B. The pain control effect, adverse reactions and the 36-item shot-form health survey (SF-36) score were compared between the two groups. Costs of the two regimens was summarized to conduct cost-utility analysis using the principle of pharmacoeconomics. Results: The pain control rate showed no significant difference between group A and group B (82.61% vs 85.00%, P>0.05). After treatment, the scores for physiological function (PF), role physical (RP), body pain (BP), general health (GH), social function (SF), mental health (MH), role emotional (RE) and vitality (VT) in SF-36 were significantly increased in the two groups (P<0.05), without significant difference between the groups (P>0.05). The incidence of adverse reactions was similar in group A and group B (P>0.05). The drug cost (C1) and total cost (C) in group A were (4,052.50±80.50) yuan and (4,453.87±123.56) yuan, higher than (2025.50±70.15) yuan and (2395.44±109.17) yuan in group B (P<0.05). The cost-utility ratio (CUR) was 4,189.94 in group A and 2,829.17 in group B. Conclusion: Considering the effectiveness and economy of the drug, sodium ibandronate has obvious cost-utility advantages in the treatment of bone metastasis from malignant tumors.
查看全文   查看/发表评论  下载PDF阅读器
关闭